This week, PharmaCompass continued its analysis of the top 10 fastest-growing drugs of 2016 by sales to evaluate the drugs that registered large sales growth. Please note that these are not the top-selling drugs, but are the top 10 drugs that registered the maximum growth in global sales over 2015. Interestingly, things didn’t appear that[…]
Chemical entities SHINE in the top 10 fastest-growing drugs of 2016
Anti-Retroviral / Anti-HIV, Blood Product, Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approved 2014, FDA Approved 2015 Tags: GileadPfizer May 26, 2017
Paliperidone Approved as Quarterly Therapy for Patients with Schizophrenia
Antipsychotic, Drug Research & Development API, FDA Approved 2015 Tags: Janssen PharmaceuticalsSchizophrenia Aug 21, 2015
The FDA gave the green light in late May 2015 with their approval of a quarterly dosing schedule of Paliperidone Palmitate, also known as Invega Trinza. Marketed by Janssen Pharmaceuticals this novel dosing regimen is the first ever quarterly dosing therapy for patients with Schizophrenia. Paliperidone is dispensed to patients via an intramuscular injection every[…]
Sonidegib FDA Approved as Once Daily Treatment for Locally Advanced Basal Cell Carcinoma
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approved 2015 Tags: Janssen Pharmaceuticals Aug 05, 2015
On July 24, 2015 the FDA approved Sonidegib, marketed by Novartis AG as the once daily pill Odomzoa for the treatment of locally advanced basal cell carcinoma. Specifically for patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or who are not candidates for surgery or radiation therapy. Sonidegib,[…]
CF Therapy Combination Lumacaftor and Ivacaftor Approved
Drug Research & Development API, FDA Approved 2015, Respiratory Tract Agent Tags: CFCFTRcystic fibrosis Jul 24, 2015
On July 2, 2015 the FDA announced its approval for the potent duo of Lumacaftor and Ivacaftor to treat patients suffering from Cystic Fibrosis (CF). Coined Orkambi, which is marketed by Vertex Pharmaceuticals, this effectual treatment is specifically approved for patients ages 12 and older who have the homozygous F508 mutation of the CF transmembrane[…]
Sacubitril and Valsartan Combo Entresto is FDA Approved
Anti-Hypertensive, Drug Research & Development API, FDA Approved 2015 Tags: chronic heart failure Jul 09, 2015
Entresto, the novel combination therapy which combines Sacubitril and Valsartan, was FDA approved on July 7, 2015. Previously known as the investigational compound LCZ696, Entresto received an FDA nod to reduce the risk of both hospitalization and cardiovascular mortality in patients with chronic heart failure, especially those with a reduced ejection fraction and an NYHA[…]
FDA Approves Olopatadine Hydrochloride for Ocular Itching
Anti-Inflammatory, Drug Research & Development API, FDA Approved 2015 Tags: Alconallergic conjunctivitis Apr 20, 2015
On February 3, 2015 the FDA approved Olopatadine Hydrochloride, ophthalmic solution 0.7%, for the treatment of ocular itching due to allergic conjunctivitis. Known as the brand name Pazeo, which is marketed by Alcon, the approved dose is one drop in each affected eye daily. Positive data from two trials coined Conjunctival Allergen Challenge demonstrated that[…]
Edoxaban Is FDA Approved As Anticoagulant Therapy
Antithrombotic, Drug Research & Development API, FDA Approved 2015 Tags: anticoagulantWarfarin Mar 20, 2015
As an effectual oral factor Xa inhibitor, Edoxaban is FDA approved as a novel anticoagulant therapy in the U.S. as an anticoagulant in several capacities: To reduce the risk with of both systemic embolism and stroke in patients afflicted with atrial fibrillation (AF), which is not related to heart valve problems. As a treatment for patients[…]
Rizatriptan Gets FDA Nod as New Generic for Migraine Therapy
Anti-Inflammatory, Anti-Migraine, FDA Approved 2015 Tags: migraine headachesmigrainesserotoninUnited States Mar 12, 2015
On January 5, 2015 Jubilant Life Sciences received an FDA nod for their Rizatriptan generic formulation, paving the way for more generic forms of Merck’s blockbuster migraine medication Maxalt. The strengths approved for generic production are both 5 milligrams and 10 milligrams, which makes up an estimated 70 million dollar market. Rizatriptan is an efficacious[…]
